United Therapeutics Corporation $UTHR Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 10.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 89,960 shares of the biotechnology company’s stock after selling 10,894 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in United Therapeutics were worth $25,854,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. AE Wealth Management LLC bought a new position in United Therapeutics in the 1st quarter valued at about $248,000. Avantax Advisory Services Inc. lifted its stake in shares of United Therapeutics by 226.5% in the 1st quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 1,341 shares during the period. HB Wealth Management LLC boosted its holdings in shares of United Therapeutics by 12.6% in the first quarter. HB Wealth Management LLC now owns 1,200 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 134 shares in the last quarter. LPL Financial LLC increased its stake in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after acquiring an additional 11,007 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of United Therapeutics during the first quarter valued at approximately $958,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Down 0.5%

NASDAQ:UTHR opened at $485.97 on Friday. The business’s fifty day moving average price is $447.65 and its 200 day moving average price is $361.75. The firm has a market capitalization of $20.92 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.39 EPS. Equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 578,435 shares of company stock worth $252,731,147 over the last quarter. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on UTHR. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research note on Tuesday. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. UBS Group raised their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.